🔗 Share this article

While America proceeds with sweeping changes to its immunization guidelines, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus vaccinations during the global health crisis and has zeroed in on alleged deaths after COVID-19 vaccination in her recent time at the Food and Drug Administration.

Planned Changes to Childhood Immunization Schedule

Public health authorities planned to unveil sweeping revisions to the childhood immunization program recently, bringing the US with Denmark’s vaccine program, sources say – a major change that would put the US out of step with much of the world with insufficient data for benefit. The planned update has been postponed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is set to present at the event. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth appointee to lead the division this year.

A Shift at the FDA

The acting appointment may indicate a strengthened alliance between the pharmaceutical and biologics centers as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it signals a renewed priority upon reevaluating already-approved immunizations at the FDA.

Høeg has often pushed for ending certain pediatric immunization guidelines in the US to become more like Denmark, a nation with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far comments, she has continued to focus on vaccines – traditionally the domain of Dr. Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Expertise

Dr. Høeg has no apparent experience in drug development, regulation or leadership, which has been standard for previous heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“It seems she lacks to have the necessary background” for leading the CDER, said Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in leading a major agency. She is not an expert in industry regulation.”

Past heads of the center would “be deeply familiar with legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that previous people who ran CBER have had.”

CDER has an vast workload at the agency, Woodcock pointed out.

“Everybody just focuses on the innovative therapies, but the generic drug division authorizes thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and so forth, and every single one need to be looked after,” she explained. “The area you overlook, that’s the thing that I always told people is going to come back to haunt you.”

Additionally, a substantial management element to the job, which oversees in excess of 5,000 personnel. “It is a enormous leadership role, if you perform it correctly,” the former official added.

Official Statement and Controversial Programs

When asked about questions about Høeg’s fitness for the role and whether this appointment indicates more teamwork among regulatory chiefs on immunizations, a press secretary said that the “inquiries stem from incorrect assumptions”.

“This background is consistent with the duties of her role,” the official said, citing the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Høeg inherits the agency head's recently launched priority voucher program, a controversial rapid therapy clearance system that reportedly concerned her former heads. “How are these drugs being selected for this expedited pathway? Who takes the choices?” Howard said. “There’s a lot of confidentiality happening at the agency right now.”

Overall, he remarked, “the FDA seems to be moving towards less stringent rules of most medications, aside from vaccines.”

Documented Track Record on Immunizations

With immunizations, Dr. Høeg has a more established, if concerning, past, some experts have noted. She released a analysis using unconfirmed crowd-sourced reports to assess the rate of heart inflammation after COVID-19 immunization. She advised the Florida chief medical officer Joseph Ladapo, who allegedly have modified findings to imply COVID-19 vaccines are riskier than they are.

Included in her “wish list” for the current administration included altering rules for recently developed shots and ending “unnecessary” vaccines, she stated after the election on a online show. At the FDA, Dr. Høeg has allegedly floated the idea of preventing teenage boys from getting Covid vaccines.

“She’s an complete ideologue who commences with her conclusions and reverse-engineers to fit the evidence in a highly disingenuous, untruthful fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow skeptics, {like|